Literature DB >> 10644373

Varicella-zoster virus proteins in skin lesions: implications for a novel role of ORF29p in chickenpox.

P W Annunziato1, O Lungu, C Panagiotidis, J H Zhang, D N Silvers, A A Gershon, S J Silverstein.   

Abstract

Skin biopsy samples from varicella-zoster virus (VZV)-infected patients examined by immunohistochemistry demonstrated VZV replication in nonepithelial cell types. ORF29p, a nonstructural nuclear protein, was found in nerves of two of six patients with chickenpox. In tissue culture, ORF29p was secreted by VZV-infected fibroblasts. Extracellular ORF29p can be taken up through endocytosis by human neurons, implying a novel role for this protein in pathogenesis.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10644373      PMCID： PMC111678          DOI： 10.1128/jvi.74.4.2005-2010.2000

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  26 in total

1.  THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS.

Authors:  R E HOPE-SIMPSON
Journal:  Proc R Soc Med       Date:  1965-01

2.  Chronic varicella-zoster virus skin lesions in patients with human immunodeficiency virus are related to decreased expression of gE and gB.

Authors:  A F Nikkels; B Rentier; G E Piérard
Journal:  J Infect Dis       Date:  1997-07       Impact factor: 5.226

3.  Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA.

Authors:  R J Cohrs; M Barbour; D H Gilden
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

4.  Latent varicella-zoster virus is located predominantly in neurons in human trigeminal ganglia.

Authors:  P G Kennedy; E Grinfeld; J W Gow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

5.  Reactivated and latent varicella-zoster virus in human dorsal root ganglia.

Authors:  O Lungu; P W Annunziato; A Gershon; S M Staugaitis; D Josefson; P LaRussa; S J Silverstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

6.  Characterization of viremia at different stages of varicella-zoster virus infection.

Authors:  C Mainka; B Fuss; H Geiger; H Höfelmayr; M H Wolff
Journal:  J Med Virol       Date:  1998-09       Impact factor: 2.327

7.  Aberrant intracellular localization of Varicella-Zoster virus regulatory proteins during latency.

Authors:  O Lungu; C A Panagiotidis; P W Annunziato; A A Gershon; S J Silverstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

8.  Detection of varicella-zoster virus DNA in the oropharynx and blood of patients with varicella.

Authors:  M H Sawyer; Y N Wu; C J Chamberlin; C Burgos; S K Brodine; W A Bowler; A LaRocco; E C Oldfield; M R Wallace
Journal:  J Infect Dis       Date:  1992-10       Impact factor: 5.226

9.  Comparative immunohistochemical study of herpes simplex and varicella-zoster infections.

Authors:  A F Nikkels; S Debrus; C Sadzot-Delvaux; J Piette; P Delvenne; B Rentier; G E Piérard
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

10.  Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella.

Authors:  C M Koropchak; G Graham; J Palmer; M Winsberg; S F Ting; M Wallace; C G Prober; A M Arvin
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226
View more
  9 in total

1.  Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus.

Authors:  M H Sommer; E Zagha; O K Serrano; C C Ku; L Zerboni; A Baiker; R Santos; M Spengler; J Lynch; C Grose; W Ruyechan; J Hay; A M Arvin
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  Varicella-zoster virus infection of human dorsal root ganglia in vivo.

Authors:  Leigh Zerboni; Chia-Chi Ku; Carol D Jones; James L Zehnder; Ann M Arvin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-25       Impact factor: 11.205

3.  Absence or overexpression of the Varicella-Zoster Virus (VZV) ORF29 latency-associated protein impairs late gene expression and reduces VZV latency in a rodent model.

Authors:  Jeffrey I Cohen; Tammy Krogmann; Lesley Pesnicak; Mir A Ali
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

4.  Simian Varicella Virus Pathogenesis in Skin during Varicella and Zoster.

Authors:  Ravi Mahalingam; Brittany Feia; Colin Coleman; Kusala Anupindi; Pratush Saravanan; Amalia Luthens; Amalia Bustillos; Arpita Das; Eileen de Haro; Lara Doyle-Meyers; Jayme Looper; Andrew N Bubak; Christy S Niemeyer; Brent Palmer; Maria A Nagel; Vicki Traina-Dorge
Journal:  Viruses       Date:  2022-05-27       Impact factor: 5.818

Review 5.  The Biology of Varicella-Zoster Virus Replication in the Skin.

Authors:  Cristina Tommasi; Judith Breuer
Journal:  Viruses       Date:  2022-05-06       Impact factor: 5.818

6.  Open reading frame S/L of varicella-zoster virus encodes a cytoplasmic protein expressed in infected cells.

Authors:  G W Kemble; P Annunziato; O Lungu; R E Winter; T A Cha; S J Silverstein; R R Spaete
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  Simian varicella virus infection of Chinese rhesus macaques produces ganglionic infection in the absence of rash.

Authors:  Werner J D Ouwendijk; Ravi Mahalingam; Vicki Traina-Dorge; Geert van Amerongen; Mary Wellish; Albert D M E Osterhaus; Don Gilden; Georges M G M Verjans
Journal:  J Neurovirol       Date:  2012-03-08       Impact factor: 2.643

Review 8.  Molecular Aspects of Varicella-Zoster Virus Latency.

Authors:  Daniel P Depledge; Tomohiko Sadaoka; Werner J D Ouwendijk
Journal:  Viruses       Date:  2018-06-28       Impact factor: 5.048

9.  T-Cell tropism of simian varicella virus during primary infection.

Authors:  Werner J D Ouwendijk; Ravi Mahalingam; Rik L de Swart; Bart L Haagmans; Geert van Amerongen; Sarah Getu; Don Gilden; Albert D M E Osterhaus; Georges M G M Verjans
Journal:  PLoS Pathog       Date:  2013-05-09       Impact factor: 6.823
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.